Part 1. Introduction.- 1. HSCT: Historical perspective.- 2. The EBMT: History, present and future.- 3. The role of unrelated donor registries in HSCT.- 4. The HSCT Unit.- 5. JACIE accreditation of HSCT programs.- 6. Statistical methods in HSCT and Cellular Therapies.- Part 2. Biological aspects.- 7. Biological properties of HSC: scientific basis for HSCT.- 8. Biological properties of cells other than HSC.- 9. Histocompatibility.- 10. Clinical & biological concepts for mastering Immune reconstitution after HSCT: towards practical guidelines and greater harmonization.- Part 3. Methodology and clinical aspects.- 11. Evaluation and counselling of candidates.- 12. Donor selection for adults and pediatrics.- 13. Conditioning.- 14. Bone marrow harvesting for HSCT.- 15. Mobilization and collection of HSC.- 16. Collection of HSC in children.- 17. Processing, cryopreserving, and controlling the quality of HSCs.- 18. Procurement and management of cord blood.- 19. Graft manipulation.- 20. Documentation of engraftment and chimerism after HSCT.- 21. Short and long-term controls after HSCT.- Part 4. General management of the patient.- 22. Vascular access.- 23. Transfusion support.- 24. Nutritional support.- 25. GVHD prophylaxis (immunosuppression).- 26. Management ATG (SIRS).- 27. Infections control and isolation procedures.- 28. General management of the patient; Specific aspects of children.- 29. Vaccinations.- 30. Psychological morbidity and support.- 31. Clinical relevant drug interactions in HSCT.- 32. Role of nursing in HSCT.- 33. Ethical issues in HSCT.- 34. Quality of life assessment after HSCT for pediatric and adults.- Part 5. HSCT complications and management.- 35. Neutropenic fever.- 36. Bacterial infections.- 37. Invasive fungal infections.- 38. Viral infections .- 39. Other life-threatening infections.- 40. Bleeding and thrombotic complications.- 41. Graft failure.- 42. Early complications of endothelial origin.- 43. Acute Graft-versus-Host Disease.- 44. Chronic Graft-versus-Host Disease.- 45. Post-transplant lymphoproliferative syndromes.- 46. Iron overload.- 47. Secondary neoplasia (other than PTLPS).- Part 6. Specific organ complications.- 48. Ocular and oral complications.- 49. Hepatic complications.- 50. Gastrointestinal complications.- 51. Hemorrhagic cystitis and renal dysfunction.- 52. Non-infectious pulmonary complications.- 53. Neurological complications.- 54. Skin, hair and musculoskeletal complications.- 55. Cardiovascular diseases and metabolic syndrome.- 56. Endocrine disorders, fertility and sexual health.- Part 7. Prevention and management of relapse.- 57. Monitoring MRD in ALL and AML.- 58. Preventing/treating relapse with drugs.- 59. Delayed transfer of immune cells, or the art of Donor Lymphocyte Infusion.- 60. Cellular therapy with engineered T cells, efficacy and side effects.- 61. Mechanisms of Immune resistance.- 62. Regulatory Aspects of ATMP versus minimally manipulated immune cells.- Part 8. Specific modalities of HSCT and management.- 63. At-home HSCT.- 64. Umbilical cord blood transplantation in children and adults.- 65. Haploidentical HSCT.- 66. Photopheresis in adults and pediatrics.- 67. Overweight and obese patients.- 68. HSCT in elderly patients.- Part 9. Indications and results.- 69. Acute Myeloid Leukemia in adults.- 70. Acute Myeloid Leukemia in children.- 71. Acute Lymphoblastic Leukemia in adults.- 72. Acute lymphoblastic leukemia in children and adolescents.- 73. Myelodysplastic syndromes.- 74. Pediatric MDS including Refractory Cytopenia and Juvenile Myelomonocytic Leukemia.- 75. Myelodysplastic/myeloproliferative neoplasms.- 76. Myeloproliferative neoplasms.- 77. Severe aplastic anemia and PNH.- 78. Fanconi anemia and other hereditary Bone Marrow Failure syndromes.- 79. Hemoglobinopathies (Sickle Cell Disease and Thalassemia).- 80. Multiple myeloma.- 81. Systemic light chain amyloidosis.- 82. POEMS syndrome and disease produced by other monoclonal immunoglobulins.- 83. Follicular lymphoma.- 84. Chronic lymphocytic leukemia.- 85. Diffuse large B cell lymphoma.- 86. Mantle cell lymphoma.- 87. Other T- and B-aggressive lymphomas and lymphomas associated to HIV.- 88. Classical Hodgkin's lymphoma.- 89. Primary immunodeficiencies.- 90. Inborn error of metabolism and osteopetrosis.- 91. Autoimmune disease.- 92. Solid tumors